<code id='70B39C8F27'></code><style id='70B39C8F27'></style>
    • <acronym id='70B39C8F27'></acronym>
      <center id='70B39C8F27'><center id='70B39C8F27'><tfoot id='70B39C8F27'></tfoot></center><abbr id='70B39C8F27'><dir id='70B39C8F27'><tfoot id='70B39C8F27'></tfoot><noframes id='70B39C8F27'>

    • <optgroup id='70B39C8F27'><strike id='70B39C8F27'><sup id='70B39C8F27'></sup></strike><code id='70B39C8F27'></code></optgroup>
        1. <b id='70B39C8F27'><label id='70B39C8F27'><select id='70B39C8F27'><dt id='70B39C8F27'><span id='70B39C8F27'></span></dt></select></label></b><u id='70B39C8F27'></u>
          <i id='70B39C8F27'><strike id='70B39C8F27'><tt id='70B39C8F27'><pre id='70B39C8F27'></pre></tt></strike></i>

          Home / comprehensive / hotspot

          hotspot


          hotspot

          author:fashion    Page View:6235
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In